Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe official Wegovy pen instructions are published in the Patient Information Leaflet (PIL) included with every pen and available as a PDF on the electronic Medicines Compendium (eMC). That leaflet covers injection technique, storage, missed doses, and what to do with used pens — everything Novo Nordisk and the MHRA require you to know before your first injection. Wegovy (semaglutide) is a prescription-only medicine, so while the instructions are freely readable, the decision about which dose you use and when to change it sits with your prescriber. If you haven't yet been assessed, starting a free consultation is the right first step.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A reasonable question, and the short answer is: use both. The leaflet inside the box is the version that was printed for that specific batch and licence iteration. The Wegovy SmPC and patient leaflet on the eMC are updated electronically whenever Novo Nordisk or the MHRA revises the labelling, so they may contain more current wording. In practice the core injection steps change rarely, but storage windows, handling after freezing, and cautionary notes are the sections most likely to be updated. Keeping both is the safest approach.
There is a common misconception that the PDF floating around health forums is "the official one" because it has a Novo Nordisk logo on it. Printed copies circulate after licence amendments, so any copy you find via a search engine could be out of date. The eMC version carries a published revision date, which makes it easy to check freshness.
You can find further context on how the pen itself is designed (including the four-dose mechanism and auto-needle cover) on our Wegovy pen overview, which covers the hardware before you get to technique.
The PIL walks through every step: inspecting the liquid for clarity and colour, attaching the needle cap, choosing an injection site (abdomen, thigh, or upper arm), pinching or not pinching the skin, pressing the button, and confirming the dose counter returns to zero. Those mechanics are consistent across the 0.25mg through to the 2.4mg (and now 7.2mg) pens.
What the leaflet does not do is tell you when to move to the next dose strength. That timing is a clinical decision, not a mechanical one. The NHS semaglutide patient information confirms that the titration schedule is agreed with your prescriber and depends on how well you are tolerating the current dose. If you are experiencing significant nausea or vomiting at your current strength, moving up sooner because the leaflet shows the next step is not the right call without talking to your prescriber first.
Injection sites matter more than many people realise. Rotating between the abdomen, thigh and upper arm (and not reusing exactly the same spot within the same site) reduces the risk of skin changes at the injection point. The leaflet is explicit about this; so is our guide to Wegovy injections, which covers technique in plain language.
This is the section of the PIL most worth reading carefully, because the numbers are specific and the consequences of getting them wrong include the medicine losing potency. Wegovy must be refrigerated at 2–8°C when not in use. The leaflet sets out a maximum room-temperature window for pens you are actively using, refer to the current eMC document for the exact duration, because that figure is the one the MHRA monitors and updates.
Do not freeze the pen. If it has been frozen, even accidentally, the leaflet instructs you to discard it. Never use a pen if the liquid looks cloudy, discoloured, or contains visible particles.
For anything beyond day-to-day storage (travelling abroad, keeping a spare pen in a bag, what to do during a power cut) our Wegovy storage instructions page covers the practical scenarios the PIL summarises only briefly. Good storage habits also matter if you are switching from Ozempic, which some readers research alongside semaglutide for weight management; our Ozempic and weight-loss injections explainer clarifies why Ozempic is licensed for type 2 diabetes rather than weight management, which affects how any advice about it applies to you.
Every used Wegovy pen is clinical waste. The needle inside the auto-cover is retracted after injection but the pen itself should go into an approved sharps container, not a household bin. The PIL states this clearly. If your prescriber or the service you use has not supplied a sharps bin, a 1-litre sharps container is an inexpensive and widely stocked addition to your routine.
Local councils and some pharmacies accept sealed sharps containers for disposal, check with your local authority, because the rules differ by area. Never recap a used needle or attempt to remove it manually.
If you are new to the pen and want to work through the full injection sequence before your first dose, the step-by-step Wegovy pen instructions page walks through each stage with the PIL as its reference. And if you are still deciding whether semaglutide or tirzepatide is the right route for you, our Wegovy overview sets out the clinical context without the sales pitch. A prescriber will work through that decision with you properly, the consultation is free, and the clinical review happens the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.